CS1001+ Fluorouracil+Cisplatin — Competitive Intelligence Brief

CS1001+ Fluorouracil+Cisplatin (CS1001+ Fluorouracil+Cisplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor + chemotherapy combination. Area: Oncology.

phase 3 PD-L1 inhibitor + chemotherapy combination PD-L1 Oncology Small molecule

Target snapshot

CS1001+ Fluorouracil+Cisplatin (CS1001+ Fluorouracil+Cisplatin) — CStone Pharmaceuticals. CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CS1001+ Fluorouracil+Cisplatin TARGET	CS1001+ Fluorouracil+Cisplatin	CStone Pharmaceuticals	phase 3	PD-L1 inhibitor + chemotherapy combination	PD-L1
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Avelumab (MSB0010718C)	avelumab-msb0010718c	Pfizer	marketed	Monoclonal antibody	PD-L1
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor + chemotherapy combination class)

1. CStone Pharmaceuticals · 1 drug in this class